Article Text

Download PDFPDF
Original research
Premature ventricular complexes and development of heart failure in a community-based population
  1. Worawan B Limpitikul1,
  2. Thomas A Dewland2,
  3. Eric Vittinghoff3,
  4. Elsayed Soliman4,
  5. Gregory Nah2,
  6. Christina Fang2,
  7. David S Siscovick5,
  8. Bruce M Psaty6,
  9. Nona Sotoodehnia7,
  10. Susan Heckbert6,
  11. Phyllis K Stein8,
  12. John Gottdiener9,
  13. Xiao Hu10,
  14. Ralf Hempfling11,
  15. Gregory M Marcus2
  1. 1 Medicine, University of California San Francisco, San Francisco, California, USA
  2. 2 Division of Cardiology, Electrophysiology Section, University of California San Francisco, San Francisco, California, USA
  3. 3 Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
  4. 4 Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
  5. 5 New York Academy of Medicine, New York, New York, USA
  6. 6 Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, Washington, USA
  7. 7 Division of Cardiology, University of Washington, Seattle, Washington, USA
  8. 8 Cardiovascular Division, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA
  9. 9 Cardiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
  10. 10 Duke University School of Nursing, Durham, North Carolina, USA
  11. 11 Vivonetics, Newport Coast, California, USA
  1. Correspondence to Dr Gregory M Marcus, Division of Cardiology, Electrophysiology Section, University of California San Francisco, San Francisco, CA 94143, USA; Greg.Marcus{at}ucsf.edu

Abstract

Objective A higher premature ventricular complex (PVC) frequency is associated with incident congestive heart failure (CHF) and death. While certain PVC characteristics may contribute to that risk, the current literature stems from patients in medical settings and is therefore prone to referral bias. This study aims to identify PVC characteristics associated with incident CHF in a community-based setting.

Methods The Cardiovascular Health Study is a cohort of community-dwelling individuals who underwent prospective evaluation and follow-up. We analysed 24-hour Holter data to assess PVC characteristics and used multivariable logistic and Cox proportional hazards models to identify predictors of a left ventricular ejection fraction (LVEF) decline and incident CHF, respectively.

Results Of 871 analysed participants, 316 participants exhibited at least 10 PVCs during the 24-hour recording. For participants with PVCs, the average age was 72±5 years, 41% were women and 93% were white. Over a median follow-up of 11 years, 34% developed CHF. After adjusting for demographics, cardiovascular comorbidities, antiarrhythmic drug use and PVC frequency, a greater heterogeneity of the PVC coupling interval was associated with an increased risk of LVEF decline and incident CHF. Of note, neither PVC duration nor coupling interval duration exhibited a statistically significant relationship with either outcome.

Conclusions In this first community-based study to identify Holter-based features of PVCs that are associated with LVEF reduction and incident CHF, the fact that coupling interval heterogeneity was an independent risk factor suggests that the mechanism of PVC generation may influence the risk of heart failure.

  • ventricular premature complexes
  • cardiomyopathies
  • heart failure
  • arrhythmias
  • cardiac
  • echocardiography

Data availability statement

Data may be obtained from a third party and are not publicly available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data may be obtained from a third party and are not publicly available.

View Full Text

Footnotes

  • Presented at Part of the data and the abstract included in this manuscript were electronically presented at the Heart Rhythm Society Scientific Sessions in San Diego, May 2020.

  • Contributors WBL and GMM conceived of the analysis plan. ES, CF, DSS, BMP, NS, SH, PKS and JG assisted with data collection and material support. WBL performed primary Holter data analysis with assistance of XH and RH. TAD, EV and GN performed the statistical analyses. WBL and GMM prepared the manuscript. All authors contributed to reviewing or revising the manuscript and approved the final version.

  • Funding In addition to a Resident Clinical and Translational Research Funding (RRF) and a Cardiology Innovation Award from the University of California, San Francisco, this research was supported by contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, 75N92021D00006, and grants U01HL080295 and U01HL130114 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Ageing (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Linked Articles